Day: October 26, 2021

KYOTO, Japan, Oct. 26, 2021 (GLOBE NEWSWIRE) — Nidec Corporation (TSE: 6594) (OTC US: NJDCY) today announced its consolidated financial results under the International Financial Reporting Standards (“IFRS”) for the period of April 1, 2021 through September 30, 2021. The highlights are as follows:First half net sales stood at a record high of ¥910.7 billion, 21.1% higher Y/Y. Operating profit increased 30.4% Y/Y to ¥90.2 billion. Quarterly operating profit ratio of Appliance, Commercial and Industrial Products has improved steadily. 1H/FY21 operating profit ratio of the product category reached 10.7%. Profit attributable to owners of the parent increased 38.6% Y/Y to ¥67.6 billion. Upward revision to full-year FY2021 financial forecasts. EPS: ¥115.49 (basic and diluted)Selected Consolidated Results of Operations (Unaudited)...

KYOTO, Japan, Oct. 26, 2021 (GLOBE NEWSWIRE) — Nidec Corporation (TSE: 6594; OTC US: NJDCY) (the “Company”) today announced differences between its financial forecast for the six months ended September 30, 2021 (previously announced on July 21, 2021) and the actual financial results released today. In this connection, the Company revised its financial forecast for the fiscal year ending March 31, 2022. The details are as follows:1. Differences between Projected and Actual Financial Results for Six Months Ended September 30, 2021 (IFRS)From April 1, 2021 to September 30, 2021 (Millions of yen, except for per share amounts and percentages)  For the six months ended September 30, 2021 (Reference)For the six monthsended September30, 2020  Previousforecast(July 21, 2021) Actual Change(amount) Change(percent)Net sales 800,000 910,668 110,668 13.8 % 751,794Operating...

Innofactor Plc Financial Calendar October 26, 2021, at 9:05 Finnish time Innofactor Plc’s financial information bulletins planned release dates in 2022 are:The 2021 Financial Statements Bulletin and Interim Report October−December 2021 (Q4) on Thursday, February 17, 2022 Interim Report January−March 2022 (Q1) on Tuesday, April 26, 2022 Half-Yearly Report January−June 2022 (Q2) on Thursday, July 21, 2022 Interim Report January−September 2022 (Q3) on Tuesday, October 25, 2022The Annual Report 2021 is estimated to be published on Innofactor’s web pages on Thursday, March 10, 2022. The Annual General Meeting is tentatively scheduled to be held on Thursday, March 31, 2022. Espoo, October 26, 2021 INNOFACTOR PLC Sami Ensio, CEO Additional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 2029sami.ensio@innofactor.com Distribution:NASDAQ...

Bank of Åland Plc Stock Exchange Release October 26, 2021 9.02 am Bank of Åland updates its long-term financial targets The Board of Directors of the Bank of Åland has approved the following updated long-term financial targets:Return on equity after taxes (ROE) shall exceed 15 per cent over time.The common equity Tier 1 capital ratio shall exceed the FIN-FSA’s minimum requirement by 1.75-3.0 percentage points.The payout ratio shall be 60 per cent of shareholders’ interest in profit or higher, provided that capital adequacy does not fall below target.The previous targets, which the Bank of Åland had since 2013 with only minor adjustments in their language, were: Return on equity after taxes (ROE) shall exceed 10 per cent.The Bank’s capital adequacy, primarily defined as the common equity Tier 1 capital ratio under the...

Once again higher result than last year for the Service and Car BusinessesThird quarter 2021Net turnover amounted to SEK 8,129 M (7,559), an increase of 8 per cent. Operational earnings amounted to SEK 482 M (402), an increase of 20 per cent. Profit from sales of used cars amounted to SEK 174 M, the highest ever for a single quarter. Profit for the period amounted to SEK 325 M (281) and earnings per share to SEK 3.35 (2.80). Operating cash flow amounted to SEK 582 M (1,148). During the quarter, Bilia completed the acquisitions of Upplands Motor Stockholm AB and BilDahl AB.Nine months 2021Net turnover amounted to SEK 26,875 M (21,786), an increase of 23 per cent. Operational earnings amounted to SEK 1,584 M (1,016), an increase of 56 per cent. Profit for the period amounted to SEK 1,108 M (661) and earnings per share to SEK 11.30...

  Bank of Åland PlcInterim ReportOctober 26, 2021 9.00 am Interim Report for the period January – September 2021 “We are continuing our strong growth in both Finland and Sweden. We have benefited from having continuously recruited new employees, and we have thus still had time to provide for both new and existing customers. “All our volume metrics have reached new record levels. Over the 12-month period to September 30, 2021, actively managed assets grew to EUR 8,922 M (+36 per cent), deposits to EUR 3,836 M (+11 per cent) and lending to EUR 4,591 M (+9%), This positive volume trend has also generated our highest 9-month net operating profit ever, EUR 39.0 M, which was 42 per cent higher than during the corresponding period of last year.” January – September 2021 compared to January – September 2020Net operating profit increased...

LONDON and RALEIGH, N.C., Oct. 26, 2021 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the three and nine months ended September 30, 2021 on Tuesday, November 9, 2021 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and reference conference ID 7220560:+1-888-317-6003 for callers in the United States +1-412-317-6061 for international callersA live webcast will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com, and the audio replay will be available for...

MONTREAL, Oct. 26, 2021 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it has reached an agreement with the Italian Medicines Agency, AIFA, for the reimbursement of Trogarzo® for eligible people aged 18 and older living with multi-drug resistant (MDR) HIV-1. “This agreement is an important milestone for Trogarzo® and for HIV-1 patients in Italy,” said Conor Walshe, General Manager, Europe. “Italy is the first country with a universal healthcare plan that has approved the formal reimbursement of Trogarzo® for all patients in need.  We expect to launch Trogarzo® in Italy during the current quarter and look forward to its wider commercial availability in Europe over...